(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Why home maintenance deserves a spot in the annual health and budget plans - 2Pfizer says patient dies after receiving hemophilia drug in trial
- 3A Manual for Pick High Evaluated Food Conveyance Administrations In Significant Urban communities For 2024
- 4Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 5Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
- Weeks-Long Australian LNG Outage Will Further Tighten Supply
- Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
- Israeli naval intelligence reduces Iranian threat to Strait of Hormuz
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- Egypt seeks to calm tourist fears over fallout of Iran war
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Can humans have babies in space? It may be harder than expected
- 5 High Limit Outer Hard Drives For Information Stockpiling
